Eye disease study lays groundwork for gene therapy breakthrough
NCT ID NCT04639635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a rare, inherited eye disease called CNGB1 retinitis pigmentosa that causes gradual vision loss and blindness. Researchers want to learn how the disease progresses by using eye exams and imaging tests over three years. The goal is to find the best ways to measure vision changes so that future gene therapy trials can be more effective. No treatment is given in this study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA ASSOCIATED WITH CNGB1 MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Stephen H. Tsang
New York, New York, 10032, United States
-
Eberhard Karls University Tubingen
Tübingen, Germany
-
Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts
Paris, France
-
Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich
München, Bavaria, 80336, Germany
-
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
-
Wills Eye Hospital
Philadelphia, Pennsylvania, 19107, United States